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IN a series of experiments already reported (Jolles and Greeninlg, 1960) it was
shown that heparin inhibits tumour growth, causing a reduction in the number
of takes of implanted tumour (Sarcoma S37) and in the rate of growth in alreadv
established tumours in mice, while in DMBA (9,10-dimethyl-1,2-benzanthracene)
painted mice it is responsible for a more rapid initiation of tumours. The anti-
mitotic activity of heparin is generally attributed to an inhibition of ribonuclease
and desoxyribonuclease (Roth, 1952; Paff, Sugiura, Bocher and Roth, 1952) bv
interference with the metabolism of these nucleoproteins. Another mechanism of
action ofheparin, a precursor ofhyaluronic acid, is during fibrogenesis as a sulphur
transfer molecule influencing a number of reactions in growing cells. The post-
radiation heparinaemia and the increase of metachromatic substances during
cell growth in regenerating wound tissues, and in the initiation stage of carcino-
genesis (Prodi, 1955) render this polysaccharide interesting when investigating
the formation of a new stroma in transplanted tumours and stromal effects of
biologically active agents.
Following, however, the findings of Csaba, Horvath and Acs (1960) who
reported that components of heparin, namely glucuronic acid and glucosamine,
shorten the life of tumour-bearing animals by promoting neoplastic growth, it was
thought worthwhile to study the effects of a polysaccharide which liberates a
' clearing factor " probably from the vascular epithelium and does not embody
glucosamine or glucuronic acid. Laminarin, obtained from common seaweed
(Laminaria cloustoni) which is undergoing elsewhere clinical trials as an anti-
lipaemic agent in treatment and prevention of atherosclerosis (Besterman and
Evans, 1957) seemed to be a likely polysaccharide for our purpose with the
advantage of lacking the anticoagulant activity of heparin.
MATERIAL AND METHOD
Laminarin is a polysaccharide obtained from seaweed fronds, and two different
types have been obtained, (a) a soluble form from Laminaria digitata and (b) an
insoluble form obtained by steeping fronds of Laminaria cloustoni in dilute acid
and collecting the precipitate. The product used in theexperiments here described
is a sulphated degraded laminarin (LM115) derived from Laminaria cloustoni in
which it is the storage carbohydrate. Chemically it is essentially a polysaccharide
consisting of /3 1: 3 linked glucose units. There are also a few , 1: 6 linked units
suggesting the presence of chain branching. Sulphation of laminarin gives a
variety of products depending on the molecular weight of the starting material
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coagulant properties similar to those of heparin but too toxic for clinical use. By
fractionation before sulphation of lower-sulphated laminarin relatively non-toxic
products can be obtained with low anticoagulant activity. The main interest in
such products is in experimental treatment of atherosclerosis. Despite their low
anticoagulant activity they resemble heparin in modifying plasma lipids through
the production of " clearing factor " (lipoprotein lipase). The most noticeable of
these changes are a clearing of alimentary lipaemia, increased rate of electro-
phoretic migration of the beta lipoprotein and disappearance of the pre-/i-band.
The ratio cx//, lipoproteins increases in patients receiving laminarin. The product
with the reference LM115 used in the experiments, and kindly supplied by Mr. R.
Cobb, B.Sc., of Boots Pure Drug Co. Ltd., Nottingham, differs from earlier
material in being more homogeneous and having a lower molecular weight. It
differs from heparin in not containing glucosamine and glucuronic acid.
Two-hundred-and-eighty-one male T.1 strain white mice with a body weight
of 25-35 g. were used. Small pieces of sarcoma (S.180) were implanted sub-
cutaneously in the suprascapular region of the mice. In each series of experiments
some mice served as controls and received no injections. In two series salinie
injections were used as controls saline being injected in approximately the same
amount as the laminarin sulphate solution in the experimental groups. The
strength of the laminarin was such that each mouse received 0-1 ml. solution!
10 g. body weight. The doses of LM115 tested were 10, 20 and 40 mg. kg. and
each mouse received eight injections in 10 days. In the majority the injections
were given into the site of transplant, commencing 2 days after transplant, but
in three groups the injections were started at 6-10 days after transplant when the
tumours had reached a measurable size, and were then given into the centre of
the tumour.
In Table I are set out the numbers of animals used in the various ranges.
TABLE I
Conttrols . No injections 82
Saline injections 1')
Ltainaria . 10 IIlg./kg. into site of transp)lant. 82
20 ,, ,,,,,, ,. 20
40 ,, ,0,,,, ,, 20
10 mlig./kg. inito gl'owinig tuinours. 52
Total: 28s
Three mice with growing tumours, about 12 x 10 mm. in size, received inltra-
peritoneal injections of MLM115, 80 mg./kg., and were killed at 1, 3 and 6 days
after injection. The mice were numbered by ear clipping and observed for per-
centage of " takes " and the growth rate was obtained by measuring the length
and width of tumours two or three times weekly. Pieces of tumour from various
groups were removed for histological examination fixed in ethanol (ethanol 50 ml.,
5 aminoacridine hydrochloride 0 4 g., water 50 ml.) for 48 hours, dehydrated,
mounted in wax and sectioned, stained with haematoxilin-eosin and toluidine blue.
the number of mitoses in the tumour was counted and particular attention was
paid to metachromasia, counts of mast cells in the growing edge of the tumour
being made regularly. Several organs were also examined from the three mice
which received laminarin intraperitoneally.
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RESULTS
The results are shown in the tables and graphs. In Tables II and III are set
out the series of experiments in which the injections were started 2 days after
transplant, and in Table IV these results are summarised by averaging the ob-
servations made in each series. The results shown include the percentage of takes.
the time taken to reach a certain size (a product of length x breadth of tumour
in millimetres), and the size of the tumours after certain time intervals. The
increase in size of tumours in the control, saline and laminarin injected mice is
plotted agaiinst time in Fig. 1, 2 and 3.
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Fi(.. 1.-Average growth r-ate in each of five groups of experinenits.
Observations regardinig the series of experiments in which inijections inito grow-
inig tumours were started 6 10 days after transplant are showni in Table IV", and
the average of these results in Table V.
The fin-dings suggest that laminarin- sulphate (LM115) inijected immediately
after transplant for 8 out of 10 days has an inhibitory effect oni the growth of
tumours. The eff-ect on already established tumours is slower to show itself and
is not apparent until 17 days after transplant, but this is only 9 days after the first
inijection and is therefore comparable to the other results.
The histological study of tumours removed from mice treated with laminiarin
did niot give conclusive data. The number of mast cells in ten random fields at the
growing edge of the tumour, and mitotic figures in similar areas of tumour tissue.
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FIG. 2.-Growth rate of individual tumours in one group of experiments.
TABLE II.-Effect ofLaminarin Sulphate (LM115) on Growth of S180 Tumour
Summary of experiments in which injections commenced 2 days after
transplant, and were given 8 times in 10 days.
Experi- Number
ment of
number mice
L.S.9 . 21
24
L.S.10 . 12
17
L.S.ll . 23
24
L.S.13 10
10
10
10
L.S.15 . 9
9
10
10
10
Dose of
LM115
(mg./kg.)
10
10
10
Saline control
10
20
40
Saline control
10
20
40
% of
takes
76
62-5
72
64
96
91-5
100
100
100
90
89
89
100
100
90
Number
of days
to reach
size 50
13-8
18-5
10-9
14-9
11.5
17-3
12-1
12-3
12-8
12-9
13-7
13-4
12-5
13 8
15*0
Size at
10 days
40-9
31-7
48-5
25-3
45 0
27-0
41-3
32-6
32-4
32-6
30-9
24-0
26-7
18-5
17-8
Size at
13 days
66-5
42-5
95.9
48-5
73-0
46-5
60-7
51-2
61-3
61-9
59.5
75-1
65-5
49-1
36-2
Size at
17 days
99-6
63-7
211-5
130-7
127 -0
110-0
115-3
104-7
136-0
117-7
125-0
162-7
129-0
104-0
95-2
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FIG. 3. Average tumour growth rate for all experiments.
TABLE III.-Average Results ofExperiments Summarised in Table II
Dose of
LM115
-(Control) .
Saline control
10 mg./kg. .
20 mg./kg. .
40 mg./kg. .
Number
of mice
treated
65
19
85
20
20
% of
takes
92-5
94 0
87-0
100-0
95 0
Number
of days
to reach
size 50
12*4
12 7
15*8
13-3
16-7
Size at
10 days
42*3
34- 1
28-8
25-4
25-2
Size at
13 days
73-2
67 4
48-3
54 8
45-7
Size at
17 days
133-9
136-0
101*0
119-0
105-0
TABLE IV.-Effect of Laminarin Sulphate LM115 on Growth of S180 Tumour
Summary ofexperiments in which injections were given into already grow-
ing tumours, commencing 6-10 days aftertransplant. Eightinjections were
given in 10 days.
Days
transp
Ist ir
Number of days
between to reach size Size of tumours at
)lant and A
njection 50 150 10 days 13 days 17 days
13-8 . 40.9 66-5 99-6
10 11.9 . 42-6 66-0 87-0
10.9 16-5 . 48-5 95.9 211*5
6 11-3 17-4 . 45-2 97-6 201-9
- . 8*4 14-4 . 86-7 148-0 332-5
7 . 7-8 15-2 . 90-6 130-0 248-7
- - -- CONTROL
INJECTED 10mg/kg.LM 115.
'I1f '-
D~~~~~~
I~
/0
/0
0
- 0
Experi-
ment
number
L.S.9
L.S.10
L.S.12
Number
of
mice
21
23
12
12
17
17
Dose of
LM115
(mg./kg.)
10
10
10
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TABLE V.-Average of Results of Experiments Summarised in Table VI
Number of days
Number to reach size Size of tumours at
Dose of of mice ,
LM115 treated 50 150 10 days 13 days 17 days
-(Control) . 50 11-3 -3 58-5 101-2 203-0
10 mg./kg. . . 52 . 109 . 58-9 90 3 166-4
were counted and are shown in Table VI. The time interval shown is the number
of days between the last (8th) injection of LM115 and the removal of tumour.
TABLE VI. Number of Mast Cells and Mitoses in Growing Tumours
Number of
Dose Time interval mast cells/10 fields Mitoses/10 fields
10 mg./kg. 4 hours . 29 . 45
10mg./kg. 7 days . 42 . 18
20 mg./kg. . 4 hours . 1 . 23
20 mg./kg. . 7 days . 38 35
40 mg./kg. . 4 hours . 31 . 20
40 mg./kg. . 7 days 43 . 35
Saline . 4 hours . 13 21
Saline . 7 days . 17 45
From this a correlation between the number of mast cells and the treatment
with laminarin sulphate could be deduced and an assumption made that laminarin
sulphate increases the number of mast cells in the stroma of the tumour. The
result is clearer if we disregard one animal, LS 13/16 (Table III) in which a rapid
necrosis of tumour and stroma was present as such changes were not observed in
any ofthe other laminarin treated animals ofthis group. Laminarin does not seem
to produce an effect upon the mast cells according to the dose. The effect seemed
qualitative.
These preliminary observations were not corroborated however by findings
made in alarger group oftumours andit was concluded that in thematerial studied
no significant influence by laminarin on the mast cell population could be observed.
There was no difference between the control and laminarin treated mice as
regards the number of mitoses or haemorrhages in the stromal tissues.
DIscuSSION
In this study part of a larger project of investigation of intercellular tissue
effects on tumour growth and its response to ionizing radiation and hormone
therapy, the observations on the effects of heparin on tumour growth in mice
(Jolles and Greening, 1960) have been repeated with laminarin. The interpretation
of the inhibitory effect of laminarin on the growth of transplanted tumours is of
interest, as it indicates a mechanism of action in which extracellular events play
an important role.
While views were advanced in the past (Roth, 1952; Paff, Sugiura, Bocher
and Roth, 1952) that the inhibitory effect ofheparin on tumour growth is exerted
through an inhibition of nucleic acid metabolism by an interference with various
enzymatic processes (Horn and Brunst, 1959) Jolles and Greening (1960) sug-
gested that a derangement in the collagen organisation induced by this polysac-
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charide may be responsible for its influence on the fate of tumour grafts. An
interference, for example, with the formation of a new stroma which replaces that
of the tumour graft which usually disappears within a few days can be safely
assumed. This interference by a biologically active substance with fundamental
events in connective tissue is ofgreat importance as it may throw light on tumour
growth and tumour disappearance. Lipman (1957) found a significant decrease in
the mitotic index of early ascites tumour following single but not repeated injec-
tions of heparin which acted, in his opinion, directly on cells and not through
haemorrhage. Both these mechanisms ofaction seem unlikely in the present series,
as is shown by the absence of a significant decrease in the number of mitoses and
the lack of a significant anticoagulant activity of laminarin. The results are aso
ofinterest in view ofthe findings ofCsaba, Horv6ath and Acs (1960), who observed
an enhanced tumour growth after treatment with heparin and attributed this
effect to glucosamine and glucuronic acid. The latter are not present in the
laminarin used in this series.
SUMMARY
A tumour growth inhibitory effect of sulphated degraded laminarin (LM115),
a polysaccharide obtained from seaweed fronds of Laminaria cloustoni injected at
the site of transplant of sarcoma S.180 and into already growing tumours in mice
is reported. The mechanism of action is discussed and the view advanced that an
interference with extracellular events in the stroma may play a role in the growth
retarding effect of this heparin-like substance with a very low anticoagulant
activity.
A grant from the British Empire Cancer Campaign is gratefully acknowledged.
We are indebted to Mr. R. Cobb, B.Sc., of Boots Pure Drug Co. Ltd., Not-
tingham, for supplying the laminarin sulphate (LM115), and to Mr. G. B. Dun,
M.S.R., for technical assistance and preparation of illustrations.
REFERENCES
BESTERMAN, E. M. M. AND EVANs, J.-(1957) Brit. med. J., i, 330.
CSABA, G., HORVATH, C. AND Acs, TH.-(1960) Brit. J. Cancer, 14, 362.
HORN, B. AND BRUNST, F. H.-(1959) Verh. dtsch. Ges. inn. Med., 65, 407.
JOLLES, B. AND GREENING, S. G.-(1960) Acta Un. int. Cancr., 16, 682.
LIPMAN, M.-(1957) Cancer Res., 17, 11.
PAFF, G., SUGIURA, H. T., BOCHER, C. A. AND ROTH, J. S.-(1952) Anat. Rec., 114, 499.
PRODI, G.-(1955) Nature, Lond., 175, 1130.
ROTH, J. S.-(1952) Fed. Proc., 11, 277.